StageMark Raises Series B

StageMark Inc., a Pittsburgh-based cell analysis company focused on autoimmune diseases, has raised $1.6 million in Series B funding. BioAdvance Ventures (managed by Quaker BioVentures) and the University City Science Center co-led the deal, and were joined by return backers BlueTree Capital Partners, Innovation Works, Meyer Ventures and the Pittsburgh Life Sciences Greenhouse.